Form 8-K · Current report
Labcorp 8-K, filed Sep 22, 2026
- Filed
- CIK
- 0000920148
- Accession no.
- 0000920148-26-000205
Summary
CMS released preliminary Clinical Laboratory Fee Schedule payment rates for 2027 through 2029 under PAMA, which Labcorp said are based on data not fully representative of the broader commercial laboratory market and would impose steep annual payment cuts threatening patient access to laboratory services. Labcorp reaffirmed its 2026-2029 long-term outlook, continued to back the bipartisan RESULTS Act, and said it will detail the rates' impact on its 2027 guidance when that guidance is announced in February 2027.
Key points
- CMS released preliminary Clinical Laboratory Fee Schedule payment rates covering 2027 through 2029 under PAMA on September 21, 2026.
- Labcorp said the rates are based on data it believes is not fully representative of the broader commercial laboratory market and would impose steep annual payment cuts that threaten patient access to laboratory services.
- Labcorp reaffirmed its 2026-2029 outlook: compound annual revenue growth of 5% to 8%, adjusted operating margin expansion of 75 to 150 basis points by the end of 2029, compound annual adjusted EPS growth of 8.5% to 11.5%, and free cash flow growth in line with adjusted earnings.
- Labcorp said it will provide more information on the rates' impact on its 2027 financial guidance when that guidance is announced in February 2027.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
From the filing
Item 7.01. Regulation FD Disclosure. On September 21, 2026, the Centers for Medicare & Medicaid Services (“CMS”) released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the Protecting Access to Medicare Act (“PAMA”). Labcorp Holdings Inc. (the “Company”) believes the payment rates are based on data that is not fully representative of the broader commercial laboratory market and would impose steep annual payment cuts that threaten patient access to laboratory services. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.